Relmada Therapeutics GAAP EPS of -$0.12 beats by $0.02
Relmada Therapeutics reported Q3 GAAP EPS of -$0.12, exceeding estimates by $0.02. The company's cash and investments rose to $202.1M as of September 30, 2026, up from $93.0M at the end of 2025, according to its press release.
How this was made
The 30-second read
Why it matters
The earnings beat is modest and unlikely to trigger a significant price move, but improved cash may support near‑term operations.
Market read
Micro‑cap earnings beat with limited market impact.
What to watch
Potential upcoming clinical trial milestones could drive future volatility beyond the earnings beat.
Background
Relmada Therapeutics is a clinical‑stage biopharma focused on CNS disorders. The company posted a cash balance of $202.1 million at quarter‑end.
Ticker impact
Relmada Therapeutics reported Q3 GAAP EPS of -$0.12, beating expectations by $0.02.
likely modest upward pressure as market prices in the earnings beat
EPS beat is small and cash position improved, but the company remains a microcap with limited liquidity.
Market effects
Minimal impact on the broader biotech sector; earnings beat is company‑specific.
Limited to U.S. micro‑cap investors; no broader regional effect.
None
Counterpoint
The EPS beat may be outweighed by ongoing cash burn and limited pipeline progress.
Key entities
- companyRelmada Therapeutics
Biopharma reporting Q3 earnings.



